TolmanLL. Fluorine and sulfur quinoline derivatives as anti-malarial agents. Iowa State Coll J Sci1946; 21: 46–8.
2.
ButlerAR, KhanS and FergusonE. A brief history of malaria chemotherapy. J R Coll Physicians Edinb2010; 40: 172–7.
3.
LoughlinEH, RiceJB, WellsHS. The treatment of Plasmodium falciparum malaria with a single dose antimalarial; a preliminary report of the use of hydroxychloroquine, 7-chloro-4(4-(N-ethyl-N-B-hydroxyethylamino)-1-methylbutylamino)-quinoline diphosphate. Antibiot Chemother (Northfield)1952; 2: 171–4.
4.
CornbleetT. Discoid lupus erythematosus treated with plaquenil. AMA Arch Derm1956; 73: 572–5.
5.
LewisHM, FrumessGM. Plaquenil in the treatment of discoid lupus erythematosus; a preliminary report. AMA Arch Derm1956; 73: 576–81.
6.
MullinsJF, WattsFL, WilsonCJ. Plaquenil in the treatment of lupus erythematosus. J Am Med Assoc1956; 161: 879–81.
7.
YoungMD. Amodiaquine and hydroxychloroquine resistance in Plasmodium falciparum. Am J Trop Med Hyg1961; 10: 689–93.
8.
QueenHO. Hepatic amebiasis treated with plaquenil: case report. N C Med J1960; 21: 469–70.
9.
ScullE. Chloroquine and hydroxychloroquine therapy in rheumatoid arthritis. Arthritis Rheum1962; 5: 30–6.
FoxRI, DixonR, GuarrasiV. Treatment of primary Sjogren's syndrome with hydroxychloroquine. Am J Med1988; 85: 62–7.
12.
RhodesJM, McLaughlinJR, BrownDJ. Inhibition of leucocyte motility and prevention of immune-complex experimental colitis by hydroxychloroquine. Gut1982; 23: 181–7.
13.
SalmeronG, LipskyPE. Immunosuppressive potential of antimalarials. Am J Med1983; 75: 19–24.
14.
MackenzieAH. Pharmacologic actions of 4-aminoquinoline compounds. Am J Med1983; 75: 5–10.
15.
GroupeV. Demonstration of an interference phenomenon associated with infectious bronchitis virus of chickens. J Bacteriol1949; 58: 23–32.
16.
McIntoshK, KapikianAZ, HardisonKA. Antigenic relationships among the coronaviruses of man and between human and animal coronaviruses. J Immunol1969; 102: 1109–18.
17.
McIntoshK, BeckerWB, ChanockRM. Growth in suckling-mouse brain of ‘'IBV-like'’ viruses from patients with upper respiratory tract disease. Proc Natl Acad Sci USA1967; 58: 2268–73.
18.
SperberK, KalbTH, StecherVJ. Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Res Hum Retroviruses1993; 9: 91–8.
19.
WangLF, LinJS, HuangNC. Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery. J Interferon Cytokine Res2015; 35: 143–56.
20.
SperberK, LouieM, KrausT. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther1995; 17: 622–36.
21.
SperberK, ChiangJ, ChenH. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin Ther1997; 19: 913–23.
22.
PatonNI, AboulhabJ, KarimF. Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1. Lancet2002; 359: 1667–8.
23.
HelalGK, GadMA, Abd-EllahMF. Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients. J Med Virol2016; 88: 2170–8.
24.
YaoX, YeF, ZhangM. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis2020; Mar 9. pii: ciaa237. doi: 10.1093/cid/ciaa237. [Epub ahead of print 09/03/20].
25.
GelerisJ, SunY, PlattJ. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020; doi: 10.1056/NEJMoa2012410 [Epub ahead of print 07/05/20].
26.
GautretP, LagierJC, ParolaP. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents2020: 105949 [Epub ahead of print 20/03/20]
27.
GautretP, LagierJC, ParolaP. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis2020: 101663. [Epub ahead of print 11/04/20].
28.
GendelmanO, AmitalH, BraqazziNL. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis. Autoimmun Rev2020: 102566. [Epub ahead of print 05/05/20]
29.
FrenkelM. Safety of hydroxychloroquine. Arch Ophthalmol1982; 100:841.
30.
AroraRB, LalA. Antimalarial drugs on the automaticity of sino-auricular and atrio-ventricular nodes. Indian J Med Res1963; 51: 725–32.
31.
TuffanelliD, AbrahamRK, DuboisEI. Pigmentation from antimalarial therapy. Its possible relationship to the ocular lesions. Arch Dermatol1963; 88: 419–26.
32.
ProppRP, StillmanJS. Agranulocytosis and hydroxychloroquine. N Engl J Med1967; 277: 492–3.
33.
TettSE, CutlerDJ, dayRO. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol1989; 27: 771–9.
34.
GoodMI, ShaderRI. Behavioral toxicity and equivocal suicide associated with chloroquine and its derivatives. Am J Psychiatry1977; 134: 798–601.
